BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27879264)

  • 1. Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Joyce CE; Yanez AG; Mori A; Yoda A; Carroll JS; Novina CD
    Cancer Res; 2017 Feb; 77(3):613-622. PubMed ID: 27879264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational inference of eIF4F complex function and structure in human cancers.
    Wu S; Wagner G
    Proc Natl Acad Sci U S A; 2024 Jan; 121(5):e2313589121. PubMed ID: 38266053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational inference of eIF4F complex function and structure in human cancers.
    Wu S; Wagner G
    bioRxiv; 2023 Aug; ():. PubMed ID: 37609226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
    Ma X; Li B; Liu J; Fu Y; Luo Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):66. PubMed ID: 30744688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.
    Srivastava RK; Khan J; Arumugam A; Muzaffar S; Guroji P; Gorbatyuk MS; Elmets CA; Slominski AT; Mukhtar MS; Athar M
    J Invest Dermatol; 2021 Apr; 141(4):742-753.e10. PubMed ID: 32971126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
    Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
    Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
    Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
    Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
    PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion.
    Khosravi S; Tam KJ; Ardekani GS; Martinka M; McElwee KJ; Ong CJ
    J Invest Dermatol; 2015 May; 135(5):1358-1367. PubMed ID: 25562667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
    George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
    J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
    Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
    Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse.
    Sénéchal P; Robert F; Cencic R; Yanagiya A; Chu J; Sonenberg N; Paquet M; Pelletier J
    Cell Mol Life Sci; 2021 Oct; 78(19-20):6709-6719. PubMed ID: 34559254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers.
    Wu S; Wagner G
    Cell Syst; 2021 Sep; 12(9):907-923.e6. PubMed ID: 34358439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
    Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
    Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells.
    Frosi Y; Ramlan SR; Brown CJ
    J Vis Exp; 2020 May; (159):. PubMed ID: 32421011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular cap-binding protein, eIF4E, promotes picornavirus genome restructuring and translation.
    Avanzino BC; Fuchs G; Fraser CS
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9611-9616. PubMed ID: 28827335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.
    Connor JH; Lyles DS
    J Virol; 2002 Oct; 76(20):10177-87. PubMed ID: 12239292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma.
    Zhan Y; Dahabieh MS; Rajakumar A; Dobocan MC; M'Boutchou MN; Goncalves C; Lucy SL; Pettersson F; Topisirovic I; van Kempen L; Del Rincón SV; Miller WH
    J Invest Dermatol; 2015 May; 135(5):1368-1376. PubMed ID: 25615552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
    Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
    Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
    De A; Jacobson BA; Peterson MS; Jay-Dixon J; Kratzke MG; Sadiq AA; Patel MR; Kratzke RA
    Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.